Huang C Y, Cridland J S, Ivanetich K M
Biochem Pharmacol. 1987 Mar 1;36(5):689-97. doi: 10.1016/0006-2952(87)90720-9.
The hepatic microsomal cytochrome P-450 enzyme system bound and metabolized the experimental drug prizidilol. Prizidilol bound to two distinct sites on cytochrome P-450. At low concentrations (less than ca 20 microM), prizidilol bound to the substrate binding site of the enzyme and produced a Type I difference spectrum. At higher concentrations (25-190 microM), prizidilol bound to the oxygen binding site of the enzyme and produced a type II difference spectrum. Prizidilol stimulated hepatic microsomal CO-inhibitable NADPH oxidation. Prizidilol metabolism by hepatic microsomes assessed by prizidilol disappearance was inhibited by CO:O2 (80:20; v/v), SKF 525-A and metyrapone. Prizidilol disappearance was monitored using a newly developed TLC assay for prizidilol following derivatization with quinolin-3-al. The apparent binding constants (Ks), maximum extents of binding (delta Amax), Michaelis constants (Km) and maximum velocities (Vmax) for the interaction of prizidilol with hepatic microsomal cytochrome P-450 were assessed in rats pretreated or not with the inducing agents phenobarbital, beta-naphthoflavone and pregnenolone-16 alpha-carbonitrile. For the differently pretreated rats the apparent Ks values for the type I site and the type II site and the apparent Km were ca 3 microM, 150 microM and 2 microM, respectively. Apparent Vmax values varied from 20 to 70 pmol per min per mg microsomal protein. The observed effects of induction on the apparent equilibrium constants and maximum extents of binding and metabolism of prizidilol indicate that the forms of cytochrome P-450 induced by phenobarbital, pregnenolone-16 alpha-carbonitrile or beta-naphthoflavone do not play a major role in the metabolism of prizidilol. Prizidilol was also metabolized by hepatic cytosolic N-acetyltransferase. The apparent Km values for prizidilol and acetyl CoA were 0.8 and 22 microM. Apparent Vmax values were 50 and ca 2 pmol per min per mg protein for partially purified transferase and cytosol, respectively. It is concluded that the rates of oxidation and acetylation of this drug would be expected to be relatively low, being limited by low apparent Vmax values for both oxidation and acetylation.
肝脏微粒体细胞色素P - 450酶系统能结合并代谢实验药物普齐地洛。普齐地洛与细胞色素P - 450上两个不同的位点结合。在低浓度(小于约20微摩尔)时,普齐地洛与该酶的底物结合位点结合,并产生I型差异光谱。在较高浓度(25 - 190微摩尔)时,普齐地洛与该酶的氧结合位点结合,并产生II型差异光谱。普齐地洛刺激肝脏微粒体一氧化碳可抑制的NADPH氧化。通过普齐地洛消失来评估的肝脏微粒体对普齐地洛的代谢受到一氧化碳与氧气(80:20;v/v)、SKF 525 - A和甲吡酮的抑制。在用喹啉 - 3 - 醛衍生化后,使用新开发的普齐地洛薄层色谱法监测普齐地洛的消失情况。在预先用诱导剂苯巴比妥、β - 萘黄酮和孕烯醇酮 - 16α - 腈处理或未处理的大鼠中,评估了普齐地洛与肝脏微粒体细胞色素P - 450相互作用的表观结合常数(Ks)、最大结合程度(δAmax)、米氏常数(Km)和最大速度(Vmax)。对于不同预处理的大鼠,I型位点和II型位点的表观Ks值以及表观Km分别约为3微摩尔、150微摩尔和2微摩尔。表观Vmax值在每分钟每毫克微粒体蛋白20至70皮摩尔之间变化。观察到的诱导对普齐地洛表观平衡常数、最大结合程度和代谢的影响表明,苯巴比妥、孕烯醇酮 - 16α - 腈或β - 萘黄酮诱导的细胞色素P - 450形式在普齐地洛的代谢中不发挥主要作用。普齐地洛也可被肝脏胞质N - 乙酰转移酶代谢。普齐地洛和乙酰辅酶A的表观Km值分别为0.8和22微摩尔。对于部分纯化的转移酶和胞质溶胶,表观Vmax值分别为每分钟每毫克蛋白50和约2皮摩尔。结论是,预计该药物的氧化和乙酰化速率相对较低,这受到氧化和乙酰化的低表观Vmax值的限制。